Napredna pretraga

Pregled bibliografske jedinice broj: 1022880

Cerebellum in Alzheimer's disease: quercetin as a potential therapeutic


Kukolj, Marina; Langer Horvat, Lea; Šimić, Goran; Šoštarić, Brank; Branović Čakanić, Karmen; Vlahović, Dunja; Gračan, Romana; Zrinščak, Ivana; Nikolić, Barbara; Odeh, Dyana; Oršolić, Nada
Cerebellum in Alzheimer's disease: quercetin as a potential therapeutic // Book of Abstracts 7th Croatian Neuroscience Congress
Zagreb, 2019. str. 91-91 (poster, domaća recenzija, sažetak, znanstveni)


Naslov
Cerebellum in Alzheimer's disease: quercetin as a potential therapeutic

Autori
Kukolj, Marina ; Langer Horvat, Lea ; Šimić, Goran ; Šoštarić, Brank ; Branović Čakanić, Karmen ; Vlahović, Dunja ; Gračan, Romana ; Zrinščak, Ivana ; Nikolić, Barbara ; Odeh, Dyana ; Oršolić, Nada

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Book of Abstracts 7th Croatian Neuroscience Congress / - Zagreb, 2019, 91-91

Skup
7th Croatian Neuroscience Congress

Mjesto i datum
Zadar, Hrvatska, 12.-15.09.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Cerebellum, Alzheimer's disease, quercetin, therapeutic, histology

Sažetak
The cerebellum is a relatively neglected area of the Alzheimer's disease (AD) brain, probably because it was formerly thought to be spared by the disease. However, a number of pathological changes have now been revealed in the AD cerebellum, principally by immunocytochemical studies, including widespread deposits of diffuse amyloid. Diffuse plaques, also called benign plaques, occur much earlier than neuritic plaques, thus supporting the idea of a therapeutic intervention in the early stage of the disease. The aetiological mechanisms underlying the neuropathological changes in AD still remain unclear but are probably affected by environmental, genetic, and neuroinflammatory factors. This study was aimed to explore neuroprotective role of quercetin as potential therapeutic in the early stage of induced AD. Three-months-old male (n=10) highly inbred Y59 strain rats were intraperitoneally administered with: (a) 0.9% NaCl, HC control group ; (b) AlCl3 (10 mg/kg) and D-(+)- galactose (60 mg/kg), AD group ; (c) AlCl3 (10 mg/kg) and D-(+)- galactose (60 mg/kg) and quercetin (50 mg/kg), AD+Qu50 ; (d) quercetin (50 mg/kg), Qu50, per day consecutively for 28 days. The brain samples were prepared according to standard paraffin procedure. Sections of 7- 10 microns were stained with hematoxylin-eosin and modified Bielschowsky, comparable areas were analyzed by light microscopy. Changes related to neurodegenerative damage were analyzed by immunohistochemistry using the following primary monoclonal antibodies: purified (azide free) anti-β-amyloid, 17-24 (Clone: 4G8) ; CD68 (E-11) ; anti-phospho-PHF- tau pSer202/Thr205 (AT8) ; anti-tau pSer396/404 (PHF1) and Tau-001 (MC1). Diffuse cerebellar plaques were recognized by antibody 4G8 in AD and AD+Qu50 (reduced number of plaques) group, but neither tau- immunoreactive neurofibrillary tangles nor reactive astrocytes / microglial cells were seen. The results obtained suggest sensitivity of the brain to low doses of aluminium chloride and neuroprotective role of quercetin as a potential therapeutic agent in the early stage of AD.

Izvorni jezik
Engleski

Znanstvena područja
Biologija



POVEZANOST RADA


Projekt / tema
HRZZ-IP-2014-09-9730 - Hiperfosforilacija, agregacija i transsinaptički prijenos tau proteina u Alzheimerovoj bolesti: analiza likvora i ispitivanje potencijalnih neuroprotektivnih spojeva

Ustanove
Hrvatski veterinarski institut, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Centar za kliničku primjenu neuroznanosti